Understanding your vulnerabilities

Brief psychoeducation for comorbid alcohol and other drug use disorders and internalizing symptoms

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16730956

Enrollment

Registered

2023-11-15

Start date

2023-08-17

Completion date

Unknown

Last updated

2023-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance use disorder and internalizing symptoms Mental and Behavioural Disorders

Interventions

This study will investigate treatment as usual plus psychoeducation versus treatment as usual alone for comorbid substance use disorders and internalizing symptoms. For both interventions, the munici

informed consent

information material from the National Scientific Ethics Committees (as part of informed consent material)

a workbook on the experimental conditions (can be made available by request)

standard treatment (can be made available by request). During the first in-person contact, social workers and/or nurses at the participating treatment site will assess whether an individual is eligi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Seeking treatment for substance use disorder 2. Reporting 3 or more points on the Youthmap internalizing problems

Exclusion criteria

Exclusion criteria: Psychotic disorders

Design outcomes

Primary

Measure	Time frame
The expectation of a good outcome measured using the Outcome Expectancies Questionnaire at 1 and 3 months post-randomization	—

Secondary

Measure	Time frame
1. Symptoms of anxiety and depression measured using the Depression, Anxiety and Stress Scale - 21 Items (DASS-21) at 1 and 3 months 2. Level of functioning measured using the WHO Disability Assessment Schedule-5 (WHODAS-5) at 1 and 3 months 3. Knowledge of internalizing symptoms measured using qualitative interviews at the 3-month follow-up 4. Retention and treatment attendance measured using an electronic logbook to assess treatment attendance at each session, including no-shows and cancellations. Retention will be measured using time-to-event models at the time of the latest discharge from treatment, or December 31st 2024, whichever occurs first. 5. Days abstinent measured using the MapPlan at 1 and 3 months 6. Acute psychiatric care measured using both case files and interview data at 1 and 3 months post-randomization	—

Measure

Time frame

1. Symptoms of anxiety and depression measured using the Depression, Anxiety and Stress Scale - 21 Items (DASS-21) at 1 and 3 months 2. Level of functioning measured using the WHO Disability Assessment Schedule-5 (WHODAS-5) at 1 and 3 months 3. Knowledge of internalizing symptoms measured using qualitative interviews at the 3-month follow-up 4. Retention and treatment attendance measured using an electronic logbook to assess treatment attendance at each session, including no-shows and cancellations. Retention will be measured using time-to-event models at the time of the latest discharge from treatment, or December 31st 2024, whichever occurs first. 5. Days abstinent measured using the MapPlan at 1 and 3 months 6. Acute psychiatric care measured using both case files and interview data at 1 and 3 months post-randomization

—

Countries

Denmark

Contacts

Public ContactBirgitte Thylstrup

bt.crf@psy.au.dk+4587165336

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026